Boundless Bio C-Suite Shakeup
Ticker: BOLD · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1782303
| Field | Detail |
|---|---|
| Company | Boundless Bio, INC. (BOLD) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, officer-departure, regulation-fd
TL;DR
Boundless Bio's CMO/CSO, Dr. Peter Blume-Jensen, is out. Big changes ahead?
AI Summary
On December 6, 2024, Boundless Bio, Inc. announced the departure of Dr. Peter Blume-Jensen from his roles as Chief Medical Officer and Chief Scientific Officer. The company also reported on compensatory arrangements for its officers and provided a Regulation FD disclosure. The filing also includes information regarding the election of directors and other events.
Why It Matters
The departure of key scientific and medical officers can signal strategic shifts or challenges within a biotechnology company, potentially impacting its research and development pipeline.
Risk Assessment
Risk Level: medium — The departure of a Chief Medical Officer and Chief Scientific Officer can indicate internal issues or strategic pivots, warranting closer scrutiny of the company's future direction.
Key Players & Entities
- Boundless Bio, Inc. (company) — Registrant
- Dr. Peter Blume-Jensen (person) — Departing Chief Medical Officer and Chief Scientific Officer
- December 06, 2024 (date) — Date of earliest event reported
FAQ
Who is replacing Dr. Peter Blume-Jensen?
The filing does not specify who will replace Dr. Peter Blume-Jensen as Chief Medical Officer and Chief Scientific Officer.
What is the reason for Dr. Peter Blume-Jensen's departure?
The filing does not explicitly state the reason for Dr. Peter Blume-Jensen's departure.
Were there any new directors elected?
The filing indicates information regarding the election of directors, but does not name specific individuals elected in this report.
What specific compensatory arrangements were made for officers?
The filing mentions compensatory arrangements of certain officers but does not detail the specific arrangements in the provided text.
What is the nature of the Regulation FD disclosure?
The filing indicates a Regulation FD disclosure was made, but the specific content of the disclosure is not detailed in the provided text.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-12-12 16:05:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share BOLD Nasdaq Global Select
Filing Documents
- bold-20241206.htm (8-K) — 46KB
- bold-ex99_1.htm (EX-99.1) — 28KB
- img6362560_0.jpg (GRAPHIC) — 32KB
- 0000950170-24-135768.txt ( ) — 263KB
- bold-20241206.xsd (EX-101.SCH) — 42KB
- bold-20241206_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 12, 2024, the Company issued a press release announcing updates to its portfolio of extrachromosomal DNA ("ecDNA") directed therapy ("ecDTx") programs and to its executive leadership team. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including in Exhibit 99.1 to this report, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation by reference language in any such filing, unless the Company specifically states in such filing that such information, or a portion thereof, is to be considered "filed" rather than furnished or incorporated by reference therein.
01 Other Events
Item 8.01 Other Events. In its press release issued on December 12, 2024, the Company provided updates on its portfolio of ecDTx programs. The information in the press release set forth under the headings "Pipeline Updates" and "Forward-Looking Statements" is incorporated into this Item 8.01 by reference. Based upon its current operating plans, the Company believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its operations into 2027.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Issued on December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOUNDLESS BIO, INC. Date: December 12, 2024 By: /s/ Jessica Oien Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary